background: Home use of misoprostol for termination of pregnancy is still controversial in many countries. Acceptability of home use of misoprostol has been investigated in pregnancies below 49 days gestation. In this study, we aimed to assess efficacy, feasibility and acceptability of home use of vaginal misoprostol for medical termination of pregnancy at 50-63 days compared with gestation of below 50 days among women who chose to administer misoprostol at home.
Introduction
Medical termination of pregnancy is highly acceptable to women. Studies have shown that between 75 and 95% of women who choose medical termination of pregnancy would prefer the same method again (Winikoff, 1995) . However, many factors influence women's choice of termination method. A major obstacle in medical terminations is the need for several visits to the clinic (Winikoff, 1995) . In 1997, it was shown that medical abortion with mifepristone followed by home administration of misoprostol was a safe option up to 56 days gestation (Schaff et al., 1997) . Later studies with vaginal administration of misoprostol at home have included women with pregnancies up to 63 days gestation Creinin et al., 2007) . When medical termination of pregnancy was introduced in the USA in the year 2000, home administration of misoprostol became the standard treatment. In contrast, most countries in Europe still do not allow home use of misoprostol for termination of pregnancy. As an exception, in 2004 home administration of misoprostol was approved for clinical practice in Sweden. In a previous study, we confirmed the high acceptability of home use of orally administered misoprostol below 50 days gestation among women and their partners (Fiala et al., 2004) .
Medical abortion with 600 mg of mifepristone followed by a prostaglandin analogue was first approved in France in 1988 up to 49 days gestation. This regimen with the upper limit of 49 days became the standard in most other European countries except UK, Sweden and Norway. Recently, the European medical products agency (EMEA) approved medical abortion up to 63 days of gestation in all European countries where mifepristone is approved (www.emea.europa.eu). Furthermore, the regimen was modified to allow the use of 200 mg mifepristone followed by a prostaglandin analogue administered vaginally.
Therefore, more information is needed on acceptability of medical termination of pregnancy with home use of misoprostol between 50 and 63 days gestation in settings where clinic treatment is an option or the standard. The experience of free choice in the termination process is important to women and influences the acceptability of the chosen method for both surgical and medical abortion (Henshaw et al., 1993) . This prospective study aimed to investigate efficacy, feasibility and acceptability in home self-administration of vaginal misoprostol for medical termination of pregnancy among women with 50 -63 days gestation compared with below 50 days of gestation. The study was performed in a routine clinical setting of medical or surgical termination where the abortion method and place of misoprostol administration was performed according to the woman's free choice.
Materials and Methods
The study was conducted at the Karolinska University Hospital, Stockholm, Sweden between January 2004 and April 2007. All patients presenting for termination of pregnancy up to 63 days of gestation were given a choice of medical or surgical methods for termination of pregnancy. Women who chose medical termination of pregnancy were also given the choice of home or clinic administration of misoprostol. Gestational age was established by menstrual history and confirmed by physical examination and endovaginal ultrasound examination (vaginal probe, 7.5 MHz) measuring gestational sac diameter or crown rump length of a present fetus and using the Robinson algorithm.
Patients were included in the study if they had no contraindication for medical termination of pregnancy, were above 18 years of age, lived within 1 h of the hospital, were able to understand Swedish or English and were willing and able to co-operate with the requirements of the study. Criteria for exclusion were abnormal pregnancy and a contraindication to mifepristone or misoprostol. All women were screened for Chlamydia trachomatis and bacterial vaginosis according to the clinical routine. In case of positive screening, treatment with doxycycline and metronidazole was prescribed. Women were counselled by both a gynaecologist and by trained and experienced nurse/midwives.
The study was approved by the local ethics committee at the Karolinska University Hospital. All women gave their informed consent prior to participating in the study.
Following appropriate counselling, each woman entering the study received a single tablet of 200 mg of mifepristone (Mifegyne, Exelgyn, Paris, France), orally taken under supervision. Four tablets of misoprostol (total dose 0.8 mg) (Cytotec, Pfizer, NY, USA) were inserted into the posterior vaginal fornix by the women at home, 36 -48 h following intake of mifepristone. The women were instructed to take oral diclofenac (100 mg) and paracetamol (500 mg) plus dihydrocodeine (10 mg) as pain prophylaxis. In addition, each woman was provided with oral analgesia acetaminophen (paracetamol: 500 mg) plus dihydrocodeine (10 mg) (Citodon w , Astra Zeneca, Stockholm, Sweden) to take one to two tablets 4 -6 hourly, if required. Oral and written information was provided.
All women were asked to return for a follow-up appointment within 2 weeks of misoprostol administration at the hospital. Follow-up included physical examination and low sensitivity urinary hCG (u-hCG: 500 mU/ml cut-off, ANL Produkter AB, Alvsjo, Sweden). Ultrasound assessment, serum hCG and surgical evacuation of the uterus were undertaken if necessary.
All women were given a telephone number for contacting staff if they were concerned at any time. For each woman, the outcome of the medical regimen was classified into: (i) complete abortion (requiring no further treatment), (ii) incomplete abortion (products of conception passed but clinical or ultrasound signs of incomplete abortion), (iii) missed abortion (no products passed and ultrasound evidence of retained gestation sac but no cardiac activity) and (iv) continuing pregnancy (no products passed and cardiac activity present on ultrasound). Any unscheduled visits between initial and follow-up visits were recorded. Success was defined as complete uterine evacuation without the need for surgical intervention following administration of the regimen.
Women completed standardized, previously used (Fiala et al., 2004) , questionnaires prior to and during treatment and at follow-up. The questionnaire prior to the termination included questions concerning health and outcome of previous pregnancies. Daily symptoms diaries were completed by the women during the study period. Intensity of pain was recorded on the visual analogue scale ranging from 0 to 10 at consecutive time points before any use of extra analgesia. Use of pain medication in addition to the standard pain prophylaxis was recorded. Intensity of bleeding was reported in relation to normal menstrual bleeding on a scale from 1 (much less than menstrual bleeding) to 5 (much heavier than menstrual bleeding).
After the treatment, women were asked to fill out a questionnaire with questions about whether or not they perceived that they had received enough information concerning the treatment on a scale from 1 (complete satisfaction with the information received) to 5 (complete dissatisfaction). They were also asked to indicate on a scale from 1 (sense of complete calm and safety) to 5 (no sense of calm and safety) if they felt calm and safe after the administration of misoprostol and at the follow-up visit. Acceptability was measured through questions in which the women were asked to state if the termination procedure overall was as expected, less dramatic than expected or worse than expected and through stating their preferred choice, were they to have another medical termination of pregnancy.
Women were asked to state if they had a partner or friend present during the termination procedure. The partner/friend was asked (if approved by the patient) to evaluate on a scale from 1 (very content) to 5 (extremely discontented) whether or not they were content with their partners choice of termination method. The partners were also asked to evaluate on a scale from 1 (yes definitely) to 5 (definitely not) if they felt they could help during the termination process.
Sample size calculation was based on women's satisfaction with home administration of misoprostol below 50 days gestation. In a previous study from our group, 98% of women reported to be satisfied with their choice of home use of misoprostol (Fiala et al., 2004) . If we assumed that 90% of women with a gestation between 50 and 63 days were to report that they were satisfied with the method, 200 women in each group (below 50 days and between 50 and 63 days of gestation) give a power of 92.4% to detect a difference in satisfaction between the groups.
Continuous variables with a normal distribution were presented as means with standard deviations and comparisons were made by using the independent t test. Non-parametric continuous variables were presented as medians and ranges, assessment for normality and comparisons were made using the Mann-Whitney U test. Comparisons between groups were made using the x 2 test or Fisher's exact test as appropriate for independent nominal data. Differences were regarded as statistically significant if P , 0.05.
Results
During the study period, a total number of 2992 women with pregnancies up to 63 days of amenorrhea underwent medical termination of pregnancy in the study centre. Among them 50% were considered as eligible and were offered home administration of misoprostol and asked to participate in the study. A total of 395 women who opted for home administration of misoprostol were included in the study. All data were collected prospectively.
Of the 395 women, 203 (51.4%) were at gestations below 50 days and 192 (48.6%) were at gestations of 50 -63 days at the time of commencing treatment. There was no significant difference in age, parity or previous termination between women seeking termination in the lower or higher gestation (Table I) .
One woman in the higher gestational band was positive for Chlamydia trachomatis and subsequently treated with doxycycline prior to the termination. Metronidazole was used for treatment of vaginosis in five women in the lower gestational group and two in the higher gestational group.
Eight women, of whom two were in the higher gestational band, did not return to the hospital for a follow-up appointment. Among these eight women there was no surgery recorded. Complete abortion occurred in 199 (98%) women with gestations below 50 days and in 186 (96.9%) women with gestations of 50-63 days and did not differ between the two groups (P ¼ 0.36). Ten women required surgical intervention, of whom four were in the lower gestational band (Table II) . A total of 12 women in the lower gestational band (5.9%) and six women in the higher gestational band (3.1%) had an unscheduled visit to the hospital due to problems they believed to be associated with the termination procedure of whom seven (1.8%) required per oral antibiotics for suspected endometritis. All these women were treated on an outpatient basis. No serious infections were reported. All of the women who received antibiotics were in the higher gestational band. No patient required blood transfusion. There were no significant differences in the rates of side effects between the groups (Table III) .
There was no significant difference in experience of the medical abortion between the gestational length groups (P ¼ 0.30) (Table IV) . Furthermore, there was no significant difference between the two groups in the preference for home use of misoprostol in case of a future termination (P ¼ 0.097) (Table IV) .
At the scheduled follow-up, 66 women had a positive u-hCG, of which 33 (33/185, 17.8%) were in the lower and 33 (33/184, 17.9%) in the higher gestational age (P ¼ 0.98). The proportion of women who required extra pain medication showed no significant difference between the two gestational groups. A total of 108 (56.2%) in the higher and 119 (58.6%) in the lower gestational group required extra oral analgesia such as diclophenac, paracetamol/codeine, ibuprofen or paracetamol. The need for extra analgesia was associated with women's experiences in both the lower (P ¼ 0.035) and higher (P ¼ 0.0002) gestational band. In the lower gestational band, 77/87 (88.5%) women who needed extra pain medication would prefer home administration in the future. This did not differ from the preference of women in the higher gestational band where the corresponding proportion was 87/103 (84.5%).
When asked to state if they were satisfied with the information received, women in the lower gestational band reported equal satisfaction (median 1, range 1-5) to women in the higher gestational band (median 1, range 1 -5) on a scale from 1 -5. Bleeding in comparison with menstrual bleeding was reported to be 4 (range 1-5) on a scale from 1-5 for women in the lower gestational band and 5 (range 1-5) for women in the higher gestational band (P ¼ 0.097). Women generally felt calm directly after administration of misoprostol and reported a median of 2 (range 1-5) for women in both gestational groups on a scale from 1-5 (P ¼ 0.47). At follow-up, the corresponding numbers were even lower with a median calmness score of 1 (range 1-5) for both groups (P ¼ 0.35). There was no significant difference between (20) 2 (20) the groups in partner/friend satisfaction with the procedure (median 1, range 1-5 for both groups, P ¼ .56). Partners/friends felt they could help to a large extent (median 1, range 1 -5 in both groups) and there was no significant difference between the groups.
Discussion
Medical abortion with home administration of vaginal misoprostol was highly acceptable to both women who chose this option and their partners, when used in a clinical routine in pregnancies of 50 -63 days gestation. Efficacy, feasibility and acceptability of the treatment at this gestational length were comparable to terminations at a gestation below 50 days. In agreement with previous studies of clinic administration of the same regimen, the rate of complete terminations was high (97.5%) and not affected by the home setting (Schaff et al., 1997; Ashok et al., 1998; Schaff et al., 1999; Schaff et al., 2000; Bartley and Baird, 2002) . Due to the legal requirement in Sweden that women return for an evaluation of the outcome of treatment after medical abortion, very few women were lost to follow-up. Home administration of misoprostol for medical abortion was introduced at Karolinska University Hospital during a previous study on acceptability of the procedure (Fiala et al., 2004) . When medical abortion was introduced in Sweden in 1992, numbers of medical abortion were initially slow to increase. However, in 2003 medical abortion constituted 50% of all abortions and in 2008 64% (www.socialstyrelsen.se, The National Board of Health and Welfare). Recognizing the importance of staff counselling, the number of women choosing home administration has continuously increased as the method has gained acceptance among staff. Knowledge about this option has also increased in the general population. In this study, less than 30% of eligible women chose home administration but the number of medical abortions with home administration of misoprostol has since increased rapidly. During 2008, approximately 50% of women at the Karolinska University Hospital Family Planning Clinic who chose medical abortion chose to administer misoprostol at home.
Although the reasons for not choosing home administration were not specifically examined in this study, these reasons included not feeling safe at home and wanting the expertise of present staff, fear of blood or excessive bleeding or fear of not having adequate pain medication at home. Others do not want to tell family or friends of their abortion but do not want to have the abortion alone or do not have the privacy they wish for at home.
A possible limitation with the study was that it was not a randomized trial. However, previous studies on acceptance of medical termination of pregnancy have shown the importance of free choice of method for the termination for women to be satisfied with the treatment (Henshaw et al., 1993) . Therefore, only women who preferred home use of misoprostol were included in the present study. The study was designed to detect a 7.5% difference in acceptability with a high power (92.4%) which makes the P-value for preference of 0.097 seem less likely to be due to a type II error.
In the USA, home administration of misoprostol has become the most widely used method for medical termination of pregnancy and has been shown to be safe and effective up to 63 days gestation Creinin et al., 2007) . An important difference between Europe and the USA is that women in the USA, who choose medical termination of pregnancy, can take misoprostol at home according to the standard protocol, while women in most countries in Europe cannot choose where they want to take the treatment. Acceptability of home use of vaginal misoprostol has been insufficiently explored in settings where women have a choice of clinic administration. Recently, acceptability of medical termination of pregnancy up to 63 days in the UK has been theoretically explored through a self-completed questionnaire. It was concluded that most women would welcome the choice of having the termination at home or in a clinic. A majority of women believed they could have coped with the bleeding and pain at home (Hamoda et al., 2005) . This was confirmed in the present study and although median amount of bleeding was perceived as more in the higher gestational group, the difference in perceived amount of bleeding did not reach significance. Women in both gestational groups generally felt calm directly after administration of misoprostol, as well as at follow-up. Treatment for suspected endometritis was given to a total of 1.8% women. A limitation with the study is that the diagnosis was based on clinical observations rather than infectious parameters and bacterial cultures and therefore it is not possible to tell in how many cases the diagnosis was correct. None of these women required hospitalization and no serious infection occurred. Recently, in the USA, vaginal administration of misoprostol has been largely abandoned due to perceived risk for infection (Fischer et al., 2005) . However, in Europe vaginal administration of a prostaglandin analogue is the standard treatment for medical abortion up to 63 days of gestation since the 1980s (Fiala and Gemzell-Danielsson, 2006) . According to the clinical routine, antibiotic prophylaxis is not used in Sweden and all women undergo screening for Chlamydia trachomatis and bacterial vaginosis prior to an induced abortion. This enables partner tracing and treatment and reduces the negative impact of antibiotics on the environment.
Studies on the experience of a partner involved in an unwanted pregnancy and induced abortion are rare. In a previous study, we demonstrated the high acceptability among women and their partners with home use of orally administered misoprostol in medical termination of pregnancy below 50 days (Fiala et al., 2004) . In the present study, there was no significant difference between the groups in partner/friend satisfaction with the procedure and a majority felt they could help to a large extent. Since partners/friends were asked to give their evaluation only after approval of the patient, this may reflect that women who were satisfied with their choice of method also involved a partner/friend to a higher degree.
Home administration of vaginal misoprostol for medical abortion is now fully implemented in clinical practice in Sweden. While gestational length did not influence acceptability of the treatment further knowledge is needed on other factors that may influence women's experience of medical abortion. In both gestational groups, a majority of women who needed extra pain medication would prefer clinic administration in case of another induced abortion in the future.
